Syndax Pharmaceuticals Inc
SNDXLatest QuantConomy context for SNDX: asset profile, market coverage, scored signals, and source-linked SEC insider filings when available.
Syndax Pharmaceuticals Inc
QuantConomy has a structured record for SNDX. More descriptive asset metadata will appear here when the platform record includes it.
- Symbol
- SNDX
- Name
- Syndax Pharmaceuticals Inc
- Coverage
- 3 market/data records
- Sources
- alphavantage fmp alpaca sec nasdaq
Recent signals for SNDX
Scored rows are pulled from the same signal API used by the digests.
| Signal | Direction | Score | Observed | Reason |
|---|---|---|---|---|
| executive trade | slightly bullish | 37 | Jul 9, 09:00 PM | Metzger Michael A (Chief Executive Officer, Director) exercised options for SNDX shares ($0.21M) - 32,375 shares - [weak slightly bullish signal] |
| earnings release | neutral | 40 | Jan 12, 12:00 AM | SNDX filed an earnings release (8-K Item 2.02 - Results of Operations and Financial Condition) on 2026-01-12. Release-event signal only: confirms results were published, not the figures vs. estimates (no surprise/guidance read). |
| earnings release | neutral | 40 | Feb 26, 12:00 AM | SNDX filed an earnings release (8-K Item 2.02 - Results of Operations and Financial Condition) on 2026-02-26. Release-event signal only: confirms results were published, not the figures vs. estimates (no surprise/guidance read). |
EARNINGS signals are experimental: currently limited to neutral pre-earnings calendar awareness (no transcript analysis).
Market coverage
| Market | Exchange | Source | Asset record |
|---|---|---|---|
| SNDX | NASDAQ | alphavantage | Syndax Pharmaceuticals Inc |
| SNDX | NASDAQ | fmp | Syndax Pharmaceuticals, Inc. |
| SNDX | NASDAQ | alpaca | Syndax Pharmaceuticals, Inc. Common Stock |
Recent insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Jul 8, 2026 | Metzger Michael A | Chief Executive Officer | exercise | 32,375 | $6.38 | $206,553 | 4 on EDGAR |
| Jun 1, 2026 | Metzger Michael A | Chief Executive Officer | sale | 6,847 | $18.99 | $130,025 | 4 on EDGAR |
| Jun 1, 2026 | Goldan Keith A. | Chief Financial Officer | sale | 1,177 | $18.99 | $22,351 | 4 on EDGAR |
| Feb 9, 2026 | Metzger Michael A | Chief Executive Officer | sale | 17,159 | $21.03 | $360,819 | 4 on EDGAR |
| Feb 9, 2026 | Goldan Keith A. | Chief Financial Officer | sale | 3,410 | $21.03 | $71,705 | 4 on EDGAR |
| Jan 30, 2026 | Goldan Keith A. | Chief Financial Officer | other | 1,219 | $8.48 | $10,337 | 4 on EDGAR |
| Feb 4, 2026 | Botwood Nicholas A.J. | Head of R&D, CMO | grant | 24,000 | $0.00 | $0 | 4 on EDGAR |
| Feb 4, 2026 | Rizo Aleksandra | Director | grant | 24,000 | $0.00 | $0 | 4 on EDGAR |
| Feb 4, 2026 | Legault Pierre | Director | grant | 24,000 | $0.00 | $0 | 4 on EDGAR |
| Feb 4, 2026 | Metzger Michael A | Chief Executive Officer | grant | 73,000 | $0.00 | $0 | 4 on EDGAR |
| Feb 4, 2026 | Podlesak Dennis | Director | grant | 48,000 | $0.00 | $0 | 4 on EDGAR |
| Feb 4, 2026 | Jarrett Jennifer | Director | grant | 24,000 | $0.00 | $0 | 4 on EDGAR |
| Feb 4, 2026 | Huber Martin H. Jr. | Director | grant | 24,000 | $0.00 | $0 | 4 on EDGAR |
| Feb 4, 2026 | Katkin Keith | Director | grant | 24,000 | $0.00 | $0 | 4 on EDGAR |
| Dec 1, 2025 | Goldan Keith A. | Chief Financial Officer | gift | 1,224 | $0.00 | $0 | 4 on EDGAR |
Source: SEC filings via QuantConomy. Not investment advice.
Query SNDX context like a database.
These rows come from the QuantConomy signal, asset, market, and SEC filings API surfaces, also available to AI agents over MCP.
More: All insider trades · How to read a Form 4 · API access